TNSN04047A1 - Compositions a delitement intra-oral, acceptables du point de vue organoleptique. - Google Patents

Compositions a delitement intra-oral, acceptables du point de vue organoleptique.

Info

Publication number
TNSN04047A1
TNSN04047A1 TNP2004000047A TNSN04047A TNSN04047A1 TN SN04047 A1 TNSN04047 A1 TN SN04047A1 TN P2004000047 A TNP2004000047 A TN P2004000047A TN SN04047 A TNSN04047 A TN SN04047A TN SN04047 A1 TNSN04047 A1 TN SN04047A1
Authority
TN
Tunisia
Prior art keywords
oral
compositions
deliting
intra
organoleptically acceptable
Prior art date
Application number
TNP2004000047A
Other languages
English (en)
Inventor
Trang T Le
Blake C Ludwig
Joseph P Reo
Uday J Shah
Ken Yamamoto
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of TNSN04047A1 publication Critical patent/TNSN04047A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DES COMPRIMES A DELITEMENT ORAL; FONDANT RAPIDEMENT; ET DES PROCEDES POUR LA PREPARATION DE CES FORMES POSOLOGIQUES SONT PROPOSES. LES COMPOSITIONS SONT UTILES DANS LE TRAITEMENT OU LA PROPHYLAXIE D'UNE LARGE GAMME DE TROUBLES ET D'AFFECTIONS.
TNP2004000047A 2001-09-26 2004-03-24 Compositions a delitement intra-oral, acceptables du point de vue organoleptique. TNSN04047A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32535601P 2001-09-26 2001-09-26
PCT/US2002/030048 WO2003026697A2 (fr) 2001-09-26 2002-09-23 Compositions a desintegration orale, acceptables sur le plan organoleptique

Publications (1)

Publication Number Publication Date
TNSN04047A1 true TNSN04047A1 (fr) 2006-06-01

Family

ID=23267542

Family Applications (2)

Application Number Title Priority Date Filing Date
TNP2004000045A TNSN04045A1 (fr) 2001-09-26 2004-03-23 Compositions de valdecoxib a delitement intra-oral
TNP2004000047A TNSN04047A1 (fr) 2001-09-26 2004-03-24 Compositions a delitement intra-oral, acceptables du point de vue organoleptique.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TNP2004000045A TNSN04045A1 (fr) 2001-09-26 2004-03-23 Compositions de valdecoxib a delitement intra-oral

Country Status (25)

Country Link
US (1) US20030181501A1 (fr)
EP (2) EP1429736A2 (fr)
JP (2) JP2005506987A (fr)
KR (2) KR20040058189A (fr)
CN (2) CN1703203A (fr)
AP (2) AP2004002999A0 (fr)
AR (1) AR037239A1 (fr)
BR (2) BR0212778A (fr)
CA (2) CA2461630A1 (fr)
CO (2) CO5570659A2 (fr)
EA (2) EA200400357A1 (fr)
EC (1) ECSP045029A (fr)
GE (1) GEP20063856B (fr)
HK (1) HK1079988A1 (fr)
IL (2) IL160855A0 (fr)
IS (2) IS7178A (fr)
MA (2) MA27542A1 (fr)
MX (2) MXPA04002652A (fr)
NO (2) NO20041258L (fr)
OA (2) OA12707A (fr)
PL (2) PL369297A1 (fr)
TN (2) TNSN04045A1 (fr)
WO (2) WO2003026623A1 (fr)
YU (1) YU34804A (fr)
ZA (2) ZA200401953B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002557A1 (fr) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Compositions pharmaceutiques comprenant un ether et un inhibiteur selectif de la cyclooxygenase-2 et leur utilisations
US20050186271A1 (en) * 2004-02-24 2005-08-25 Sheskey Paul J. Process for dispersing a fluid in a mass of solid particles
KR20070040389A (ko) * 2004-08-10 2007-04-16 아지노모토 가부시키가이샤 쓴 맛이 감소된 나테글리니드 함유 제제
EP1839650A1 (fr) * 2004-12-28 2007-10-03 Eisai R&D Management Co., Ltd. Comprime a desintegration rapide et son procede de fabrication
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
KR20080080318A (ko) * 2005-12-20 2008-09-03 에자이 알앤드디 매니지먼트 가부시키가이샤 지용성 약물을 함유하는 구강내 속붕정
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) * 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
WO2007087188A2 (fr) * 2006-01-20 2007-08-02 Merck & Co., Inc. Comprimes et granules au gout masque
US20070196494A1 (en) * 2006-02-17 2007-08-23 Arnaud Grenier Low-friability, patient-friendly orally disintegrating formulations
US20110318412A1 (en) * 2006-05-19 2011-12-29 Somaxon Pharmaceuticals, Inc. Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia
CA2688389A1 (fr) * 2007-06-06 2008-12-11 Basf Se Preparation pharmaceutique pour produire des comprimes a delitement rapide
US20100184785A1 (en) * 2007-06-06 2010-07-22 Basf Se Pharmaceutical formulation for the production of chewable tablets and lozenges
EP2164460B1 (fr) * 2007-06-06 2017-08-09 Basf Se Préparation pharmaceutique pour produire des comprimés à délitement rapide
KR101903781B1 (ko) * 2007-06-06 2018-11-13 바스프 에스이 급속 붕해 정제의 제조를 위한 제약 제제
US20090048237A1 (en) * 2007-08-07 2009-02-19 Acelrx Pharmaceuticals, Inc. Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
EP2268268A2 (fr) * 2008-03-24 2011-01-05 Wockhardt Research Centre Compositions orodispersibles de rhéine ou de diacéréine
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
KR101753411B1 (ko) * 2008-11-25 2017-07-03 미쓰비시 타나베 파마 코퍼레이션 구강 내 속붕괴성정 및 그의 제조 방법
EP2440210A4 (fr) 2009-06-12 2014-01-29 Meritage Pharma Inc Procédés de traitement de troubles gastro-intestinaux
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
FR2968995B1 (fr) * 2010-12-16 2013-03-22 Sanofi Aventis Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage
CN106822007B (zh) 2015-09-11 2021-12-31 西姆莱斯股份公司 口服制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
PE10898A1 (es) * 1995-06-13 1998-03-20 American Home Prod Formulaciones orales de etodolac s (+)-
DE69621143T2 (de) * 1995-10-20 2002-11-07 Upjohn Co Blisterpackung
BR9709097A (pt) * 1996-05-17 1999-08-03 Merck & Co Inc Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária
EP0863134A1 (fr) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophényle)-3-(4-méthylesulphonylephényle)-2-cyclopentène-1-one comme inhibiteur de la cyclooxygénase-2
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
AU1930301A (en) * 1999-12-08 2001-06-18 Pharmacia Corporation Valdecoxib compositions
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6800297B2 (en) * 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
JP2004506680A (ja) * 2000-08-18 2004-03-04 ファルマシア・コーポレーション シクロオキシゲナーゼ−２阻害剤の迅速崩壊経口製剤
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物

Also Published As

Publication number Publication date
BR0212861A (pt) 2004-10-05
TNSN04045A1 (fr) 2006-06-01
IS7178A (is) 2004-03-11
IS7177A (is) 2004-03-11
WO2003026623A1 (fr) 2003-04-03
JP2005506987A (ja) 2005-03-10
IL160848A0 (en) 2004-08-31
EP1429736A2 (fr) 2004-06-23
AP2004002999A0 (en) 2004-03-31
CO5570659A2 (es) 2005-10-31
JP2005512964A (ja) 2005-05-12
CN1703203A (zh) 2005-11-30
BR0212778A (pt) 2004-12-07
EP1490035A1 (fr) 2004-12-29
NO20041532L (no) 2004-04-15
CA2461044A1 (fr) 2003-04-03
OA13060A (en) 2006-11-10
CO5570684A2 (es) 2005-10-31
NO20041258L (no) 2003-03-27
EA200400352A1 (ru) 2004-12-30
OA12707A (en) 2006-06-26
ZA200401953B (en) 2005-05-09
GEP20063856B (en) 2006-06-26
EA200400357A1 (ru) 2004-08-26
YU34804A (sh) 2006-08-17
WO2003026623A8 (fr) 2004-09-30
PL369297A1 (en) 2005-04-18
HK1079988A1 (zh) 2006-04-21
WO2003026697A2 (fr) 2003-04-03
IL160855A0 (en) 2004-08-31
ZA200402364B (en) 2005-01-13
MA27682A1 (fr) 2006-01-02
PL369298A1 (en) 2005-04-18
CN1633281A (zh) 2005-06-29
WO2003026697A3 (fr) 2003-07-03
KR20040058189A (ko) 2004-07-03
MXPA04002798A (es) 2004-07-05
AR037239A1 (es) 2004-11-03
KR20040044990A (ko) 2004-05-31
US20030181501A1 (en) 2003-09-25
AP2004002998A0 (en) 2004-03-31
MA27542A1 (fr) 2005-10-03
CA2461630A1 (fr) 2003-04-03
MXPA04002652A (es) 2004-06-07
ECSP045029A (es) 2004-04-28

Similar Documents

Publication Publication Date Title
TNSN04047A1 (fr) Compositions a delitement intra-oral, acceptables du point de vue organoleptique.
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
IT1282353B1 (it) Composizione farmaceutica, in particolare liquida, per sommanistrazione orale di ondansetron e metodi per la sua produzione
MA27132A1 (fr) Composes de n-(3-amino-2hydroxy-propyl)alkylamide substitues
TR200002207T1 (tr) Slekoksib bileşikleri.
YU92501A (sh) Levodop/karbidop/entakapon farmaceutski preparat
MA26700A1 (fr) FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION.
WO2004071431A3 (fr) Composition et methode de traitement de troubles neurodegeneratifs
WO2007038112A3 (fr) Composition pharmaceutique conçue pour ameliorer la fonction cognitive
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
BG105302A (en) Means for improving cognition
HUP0302333A2 (hu) Glatiramer-acetát (kopolimer 1) alkalmazása központi idegrendszeri rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására
HUP0402178A2 (hu) 5 HT1 antagonista hatóanyagot tartalmazó gyógyszerkészítmény
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
WO2002055062A3 (fr) Comprime pharmaceutique comprenant du mesylate de paroxetine
TNSN04056A1 (fr) Compositions de valdecoxib a delitement intra-oral preparees par un procede de sechage par pulverisation
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
NO953072L (no) Anvendelse av inhibitorer av ornitinaminotransferase for fremstilling av et medikament for behandling av Alzheimers sykdom
HUP0301847A2 (hu) Adatanszerin alkalmazása neurodegeneratív állapotok megelżzésére és kezelésére alkalmas gyógyszerkészítmények elżállítására
DE60126504D1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa
IL176217A0 (en) Pharmaceutical compositions comprising copolymer 1 for treatment of psychiatric disorders
TW200514565A (en) A pharmaceutical composition for use in the prevention and/or treatment of the oral cavity diseases caused by microorganisms